Wellington Management Group LLP Acquires 195,042 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Wellington Management Group LLP increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 197.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 293,925 shares of the biotechnology company’s stock after buying an additional 195,042 shares during the quarter. Wellington Management Group LLP owned 0.12% of BioCryst Pharmaceuticals worth $2,939,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Larson Financial Group LLC raised its position in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the period. Allworth Financial LP bought a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $52,000. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $77,000. Envestnet Portfolio Solutions Inc. purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth $81,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 5.9%

Shares of BioCryst Pharmaceuticals stock opened at $8.29 on Friday. The stock’s 50-day simple moving average is $9.69 and its 200-day simple moving average is $9.23. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -5.53 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.During the same quarter last year, the business posted $0.15 earnings per share. The firm’s revenue was up 33.6% on a year-over-year basis. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several analyst reports. Wedbush lowered their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Cantor Fitzgerald lifted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.40.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.